This article is more than 5 years old. Information may no longer be current.
RegeneRx announces proposed public offering
Click Here to Manage Email Alerts
ROCKVILLE, Md. — RegeneRx Biopharmaceuticals intends to issue units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering, the company announced in a press release.
RegeneRx plans to establish the number and price of each unit, the portion of a common share and exercise price underlying each warrant, as well as the size of the offering, once the offering is officially valued, the release said.
According to the release, RegeneRx intends to use proceeds from the proposed offering to fund several clinical studies, including compassionate use trials of its product candidate RGN-259 in patients with neurotrophic keratitis, as well as a proposed physician-sponsored trial in patients with dry eye secondary to graft-versus-host disease.
The offering is being made pursuant to a registration statement on Form S-1 the company filed last week with the Securities and Exchange Commission and will be subject to market conditions at the time the offering is priced.
Follow OSNSuperSite.com on Twitter.